HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Start Date
1/1/2017
Summary
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Detailed Description
This is a longitudinal open-ended observational study. Participants will attend two annual study visits, an Annual Screening Visit followed by an Annual Sampling Visit, and may also attend an optional visit during the first year of enrollment, an Optional Repeat Sampling Visit. During the Annual Screening Visit, medical history, and clinical and phenotypic data will be obtained. Participants who meet the eligibility requirements of the study and are willing to continue in the study, will return for an Annual Sampling Visit. During that visit, biosamples will be collected following a fast of at least 6 hours, or overnight: blood will be obtained via venipuncture and CSF will be obtained via lumbar puncture. Some participants may be invited to return for an Optional Repeat Sampling Visit approximately 4-8 weeks after the Annual Sampling Visit during their first year of enrolment. The annual visits are at regular intervals after the first Annual Screening Visit (i.e. at 1, 2, 3 years and so on) ± 2 months. Participants will be encouraged to complete all annual visits; however, they are under no obligation to take part and will be able to skip annual visit without being discontinued from the study. Participants who do not come for an Annual Sampling Visit for three consecutive years will be discontinued from the study, but they may enrol again at a later date, if they so consent. Participants who have already completed HDClarity Sampling Visits under earlier versions of this protocol may also participate in the longitudinal study if they meet the eligibility criteria.
Eligibility Criteria
Age Range: 11 years to 75 years
Conditions
Locations
Cenexel
Englewood, Colorado
United States
Georgetown University
Washington D.C., District of Columbia 20057
United States
John Hopkins University
Baltimore, Maryland 21287
United States
Wake Forest University
Winston-Salem, North Carolina 27109
United States
Vanderbilt University Medical Center
Nashville, Tennessee 37212
United States
University of Texas Health Science Center
Houston, Texas 77030
United States
University of British Columbia, The Centre for Huntingtons Disease
Vancouver, British Columbia V6T 2B5
Canada
The Ottawa Hospital
Ottawa, Ontario K1Y 4E9
Canada
North York General Hospital
Toronto, Ontario M2K 1E1
Canada
Centre for Movement Disorders
Toronto, Ontario M3B 2S7
Canada
Centre Hospitalier Universitaire d'Angers
Angers, 49000
France
Le Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33076
France
University Hospital Ulm
Ulm, Baden-Wurttemberg 89081
Germany
Dresden University
Dresden, Saxony 01307
Germany
St Josef And Elisabeth Hospital
Bochum, 44791
Germany
University Hospital of Erlangen
Erlangen, 91054
Germany
George Huntington Institute
Münster, 48149
Germany
Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)
Taufkirchen, 84416
Germany
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Milan, 20133
Italy
Lega Italiana Ricera Huntington
Rome, 00185
Italy
The University of Auckland
Grafton, Auckland 1023
New Zealand
NZ Brain Research Institute
Christchurch, Canterbury 8011
New Zealand
Institute of Psychiatry and Neurology
Warsaw, 02-957
Poland
Gulbenkian Institute of Molecular Medicine
Lisbon, 1649-028
Portugal
Cruces University Hospital
Bilbao, Biscay 48903
Spain
Hospital de Sant Pau
Barcelona, 08041
Spain
Ramón y Cajal Universitary Hospital
Madrid, 28034
Spain
Royal Devon & Exeter NHS Foundation Trust
Exeter, Devon EX2 5DW
United Kingdom
Glasgow Clinical Research Facility
Glasgow, Scotland G51 4TF
United Kingdom
Birmingham Huntingtons Disease Clinic
Birmingham, West Midlands B15 2 FG
United Kingdom
North Bristol NHS Trust
Bristol, BS10 5NB
United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0PY
United Kingdom
Cardiff University
Cardiff, CF24 4HQ
United Kingdom
Fife Health Board - Whyteman's Brae Hospital
Kirkcaldy, KY1 2ND
United Kingdom
Leeds Teaching Hospital Trust
Leeds, LS7 4SA
United Kingdom
The Walton Centre NHS Foundation Trust
Liverpool, L9 7LJ
United Kingdom
University College London Hospitals NHS Foundation Trust
London, NW1 2PG
United Kingdom
St George's University Of London
London, SW17 0RE
United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU
United Kingdom
University Hospitals Plymouth NHS Trust
Plymouth, PL6 5FP
United Kingdom